Big Pharma’s $300 Billion Problem… And Its $1.2 Trillion Solution

By Joe Austin, senior analyst, Chaikin AnalyticsIn the pharmaceutical business, there’s always some race against time.

Companies first have to prove that their drugs are safe and effective before more people get sick… or even die.

Then they have to race to get their drugs to market before a competitor comes along with something better – or cheaper.

Once in the market, the company behind the drug has to make as much money as possible before the drug goes off-patent. That’s called the patent “cliff” – when revenues start to decline.

And that patent cliff creates another race…

Pharma firms need to find new drugs to sell before their businesses start to decline.

That last race is the trickiest. And it’s often the most expensive.

When it happens, drug companies have two options…

They can invest years in risky internal research and development (R&D). Or they can acquire promising drug candidates from other companies.

Patent cliffs are nothing new in the pharma world. But a huge one is underway…

In a report late last year, pharma-data firm Evaluate stated that more than $300 billion in drug revenues globally will lose patent protection between 2025 and 2030.

Early last year, Morgan Stanley warned that $175 billion in U.S. revenues alone were at risk. That’s roughly 35% of the industry’s total revenues.

By 2028, patents for more than 70 blockbuster drugs will expire. That would put nearly half of the top 10 pharma companies’ revenues at risk.

But luckily, these firms have a huge war chest to deploy…

According to an analysis from Stifel late last year, the industry’s 18 biggest players have about $1.2 trillion in cash and borrowing power to refill their pipelines.

A mergers-and-acquisitions (M&A) frenzy lies ahead.

But unlike past cliffs, there’s a twist this time…

Big Pharma companies are no longer the main engines of innovation.

Most breakthrough drugs now come from small biotechnology firms. This means Big Pharma’s $1.2 trillion will be chasing a limited pool of promising targets.

And competition for those assets will be fierce.

The winners will secure the next generation of blockbusters. The losers will burn through billions overpaying for mediocre assets or yesterday’s science at tomorrow’s prices.

For investors, this creates both opportunities and risks…Recommended Links:

Announcing Jeff Brown’s Powerful New Model: ’24-Hour AI Fortunes’

For the first time ever, tech-investing legend Jeff Brown is revealing his brand-new, proprietary AI model designed specifically to identify a strange phenomenon that has delivered gains big enough to turn $10,000 into $101,700… $151,600… and even a mind-blowing $650,000 – all in a 24-hour period.  Click here to learn more.

January 28 (TODAY) Could Be a Critical Date for Gold

Many are wondering why so many countries are frantically buying gold now… The truth is that this is just the beginning of a much larger story – one that could soon send gold soaring to even bigger highs in the weeks ahead. But the best way to cash in on gold’s upside potential might surprise you.  Click here for this January 28 gold update.

From Innovation Crisis to Shopping Spree

For decades, the pharma industry focused on internal innovation.

One study found that from 1984 to 2001, 89% of drug development happened internally rather than through external partnerships.

But the early 2000s flipped that script. Declining R&D productivity inside Big Pharma coincided with the emergence of nimble biotech startups that were out-innovating companies 100 times their size.

Between 1998 and 2008, small biotech companies discovered nearly half of all truly innovative new drugs. They also developed about 70% of new treatments for rare diseases.

And by 2007, biotech’s share of blockbuster drugs (those with more than $1 billion in annual sales) increased from 8% to 22%.

Fast-forward to today, and the shift has accelerated.

According to consulting firm McKinsey, Big Pharma now relies heavily on outside innovation.

Since 2018, more than 70% of revenue from new drugs has come from products pharma companies bought or licensed from biotech firms rather than discovered in-house.

This shift from internal development to external sourcing has created a growing gap…

Some companies are skilled buyers. And others squander billions on bad deals.

McKinsey found that top performers in external drug acquisitions generate 3.4 to 8.2 times more value than bottom performers.

The buying frenzy has already begun…

In 2025, pharma M&A hit 585 deals worth $269.3 billion. That compares with the previous year’s 452 deals worth $137.9 billion.

And with the patent cliff looming and the industry’s $1.2 trillion war chest, this is just the beginning.

We’re likely to see a big surge in dealmaking this year. And it’s expected to include more than 20 acquisitions worth over $1 billion.

Watching Pharma and Biotech Firms in the Power Gauge

To keep an eye on all this, I’m watching two exchange-traded funds (“ETFs”) in the Power Gauge…

As you know, ETFs hold baskets of companies. So they’re a great way to gain broad exposure to a particular trend. They’re also a great starting point for digging into individual opportunities.

First up is the State Street SPDR S&P Pharmaceuticals Fund (XPH)…

Right now, the Power Gauge gives the fund a “bullish” rating. And digging deeper, 22 of XPH’s holdings are “bullish” or better. That compares with 31 in “neutral” territory… and five that are “bearish” or worse.

However, within the “neutral” holdings, nine are rated “neutral+.”

As regular readers know, a stock gets a “neutral+” rating when its share price moves below the long-term trend line. So despite a pullback, the Power Gauge still sees strength “under the hood” with “neutral+” stocks.

I’m also watching the State Street SPDR S&P Biotech Fund (XBI)…

It also earns a “bullish” rating in the Power Gauge right now. And 60 of its individual holdings receive a “bullish” or better grade…while 78 holdings are in “neutral” territory. And only eight are “bearish” or worse. 

Within XBI’s stocks in “neutral” territory, 27 are rated “neutral+.”

Put simply, the Power Gauge is already flagging strong opportunities on both sides of this M&A wave.

The patent cliff isn’t a crisis. It’s a catalyst for the biggest M&A wave pharma has seen in decades.

Companies that can identify the right targets and integrate them successfully should see their pipelines – and stock prices – soar.

There will be losers, too. But right now, this corner of the market is primed for action.

With $1.2 trillion in firepower and $300 billion in revenue to replace, the opportunity is too big to ignore. Pay attention to pharma and biotech stocks in 2026.

Good investing,

Joe Austin

Market View

Major Indexes and Notable Sectors  # HLD:    BULLISH    NEUTRAL    BEARISHDow 30

-0.81%718 5S&P 500

+0.4%113269 118Nasdaq

+0.91%2653 27Small Caps

+0.28%632960 297Bonds

-0.62%Information Technology

+1.35%2233 13

— According to the Chaikin Power Bar, Small Cap stocks are more Bullish than Large Cap stocks. Major indexes are mixed.*  *  *  *

Sector Tracker

Sector movement over the last 5 daysInformation Technology+4.38%Energy+4.35%Materials+3.71%Communication+3.02%Consumer Discretionary+3.0%Utilities+1.09%Consumer Staples+0.97%Industrials+0.94%Health Care+0.03%Real Estate-0.36%Financial-0.38%*  *  *  *

Industry Focus

Capital Markets Services20359

Over the past 6 months, the Capital Markets subsector (KCE) has underperformed the S&P 500 by -7.95%. However, its Power Bar ratio, which measures future potential, is Strong, with more Bullish than Bearish stocks. It is currently ranked #10 of 21 subsectors and has moved up 1slot over the past week.Top StocksIBKRInteractive Brokers AMPAmeriprise FinancialBKThe Bank of New York*  *  *  *

Top Movers

GainersGLW+15.58%SYY+10.96%GM+8.75%HCA+7.08%LRCX+7.0%LosersHUM-21.13%UNH-19.61%ELV-14.33%CVS-14.15%CNC-10.26%*  *  *  *

Earnings Report

Earnings SurprisesBA 
The Boeing Company Q4 $9.92 Beat by $10.31FFIV 
F5, Inc. Q1 $4.45 Beat by $0.80GM 
General Motors Company Q4 $2.51 Beat by $0.24UPS 
United Parcel Service, Inc. Q4 $2.38 Beat by $0.18SYF 
Synchrony Financial Q4 $2.18 Beat by $0.16*  *  *  *

You have received this e-mail as part of your subscription to PowerFeed. If you no longer want to receive e-mails from PowerFeed, click here.

You’re receiving this e-mail at pahovis@aol.com.

For questions about your account or to speak with customer service, call +1 (877) 697-6783 (U.S.), 9 a.m. – 5 p.m. Eastern time or e-mail info@chaikinanalytics.com. Please note: The law prohibits us from giving personalized financial advice.

© 2026 Chaikin Analytics, LLC. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Chaikin Analytics, LLC. 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. www.chaikinanalytics.com.

Any brokers mentioned constitute a partial list of available brokers and is for your information only. Chaikin Analytics, LLC, does not recommend or endorse any brokers, dealers, or investment advisors.

Chaikin Analytics forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Chaikin Analytics, LLC (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation.

This work is based on SEC filings, current events, interviews, corporate press releases, and what we’ve learned as financial journalists. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility.